“Progressive Supranuclear Palsy Epidemiology” report has been recently added to DelveInsight
About Progressive Supranuclear Palsy
Progressive Supranuclear Palsy (PSP) is a rare progressive condition that can cause problems with balance, movement, vision, speech and swallowing. The condition has been linked to changes in certain genes, but these genetic faults are not inherited and the risk to other family members (including the children or siblings) with PSP, is very low.
Get free sample copy of Progressive Supranuclear Palsy epidemiology report- https://www.delveinsight.com/sample-request/progressive-supranuclear-palsy-epidemiology-forecast
Progressive Supranuclear Palsy Epidemiology
Progressive Supranuclear Palsy (PSP) also called Steele-Richardson-Olszewski syndrome, is an uncommon brain disorder that affects movement, control of walking (gait) and balance, speech, swallowing, vision, mood and behavior, and thinking. The cause of PSP is not known, but it is a form of tauopathy, in which abnormal phosphorylation of the protein tau leads to destruction of vital protein filaments in nerve cells, causing their death.
Important facts of Progressive Supranuclear Palsy Epidemiology report
Progressive Supranuclear Palsy Diagnosis
There’s no single test for PSP. Instead, the diagnosis is based on the pattern of the symptoms. The large number of possible symptoms of PSP also makes it difficult to diagnose correctly and can mean it takes a while to get a definitive diagnosis. Apart from this, PSP is often misdiagnosed as Parkinson disease, Alzheimer disease, corticobasal degeneration and other neurodegenerative disorders.
Progressive Supranuclear Palsy Epidemiology Segmentation
Progressive Supranuclear Palsy Treatment
Treatment of PSP is symptomatic and supportive. There is no cure of the disease at the present time. Drugs prescribed to treat Parkinson’s disease, such as ropinirole, rarely provide additional benefit. In some individuals the slowness, stiffness, and balance problems of PSP may respond to some degree to antiparkinsonian agents such as levodopa, but the effect is usually minimal and short-lasting. Excessive eye closing can be treated with botulinum injections. Some antidepressant drugs may provide benefit beyond treating depression, such as pain relief and decreasing drooling.
Progressive Supranuclear Palsy Epidemiology: Report Scope
Following is the table of content of Progressive Supranuclear Palsy epidemiology report
1 Key Insights
2 Executive Summary of Progressive Supranuclear Palsy
3 SWOT Analysis for Progressive Supranuclear Palsy
4 Progressive Supranuclear Palsy (PSP) Epidemiology Overview at a Glance
5 Disease Background and Overview: Progressive Supranuclear Palsy (PSP)
6 Epidemiology and Patient Population
7 Country Wise-Epidemiology of Progressive Supranuclear Palsy (PSP)
8 Treatment
9 Unmet Needs
10 Appendix
11 DelveInsight Capabilities
12 Disclaimer
13 About DelveInsight
What are the reasons to buy this report?
Related Reports
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/